Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019

Abstract

Background Currently, only dexamethasone, tocilizumab and sarilumab have conclusively been shown to reduce mortality of COVID-19. Safe and effective treatments will need to be both affordable and widely available globally to be used alongside vaccination programmes. This analysis will estimate and compare potential generic minimum costs of a selection of approved COVID-19 drug candidates with available international list prices. Methods We searched for repurposed drugs that have been approved by at least one of the WHO, FDA or NICE, or at least given emergency use authorisation or recommended for off-label prescription. Drug prices were searched for, for dexamethasone, budesonide, baricitinib, tocilizumab, casirivimab and imdevimab, and sarilumab using active pharmaceutical ingredients (API) data extracted from global shipping records. This was compared with national pricing data from a range of low, medium, and high-income countries. Annual API export volumes from India were used to estimate the current availability of each drug. Results Repurposed therapies can be generically manufactured for some treatments at very low per-course costs, ranging from $2.58 for IV dexamethasone (or $0.19 orally) and $4.34 for inhaled budesonide. No export price data was available for baricitinib, tocilizumab, casirivimab and imdevimab or sarilumab, but courses of these treatments are priced highly, ranging from $6.67 for baricitinib to $875.5 for sarilumab. When comparing international list prices, we found wide variations between countries. Conclusions Successful management of COVID-19 will require equitable access to treatment for all populations, not just those able to pay high prices. Dexamethasone and budesonide are widely available and affordable, whilst monoclonal antibodies and IV treatment courses are more expensive.

Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies

“…Although vaccine coverage has increased rapidly, many regions remain at risk of COVID-19-related health pressures because of inequitable access to COVID-19 vaccines globally [ 6 ]. Medication use for treatment and prevention is still an important strategy alongside vaccine rollout [ 7 ]. Remdesivir and other antivirals are increasingly prescribed in hospital settings.…”

Concessão rápida de patentes para enfrentamento da COVID-19 no Brasil

“…Particularmente, o Sistema Único de Saúde (SUS) do Brasil, maior sistema público de saúde do mundo, gastou apenas com medicamentos cerca de 85% do seu orçamento, R$17,1 bilhões em 2017, considerando os gastos das três esferas de governo (federal, estadual e municipal) ( 8 ). Os tratamentos com anticorpos monoclonais, como tocilizumabe e sarilumabe, certamente impulsionarão os gastos, visto que custam várias centenas de dólares (cerca de US$650/dose no mercado indiano) e exigem biorreatores complexos para serem produzidos ( 9 ).…”

The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 – A formulator’s perspective

“…Several drugs from the antiviral and anti-parasitic arsenal were considered and attempted on patients, but often with limited success, side effects and/or cost constraints [3] , [4] . Cost and availability often place these advanced drug treatments out of reach of many populations especially in third world countries where it is so urgently needed [5] .…”